ALT News

Latest breaking news and updates for ALT stock.

Track all markets on TradingView

ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc.

SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) secu...

How might the lawsuit affect ALT's ability to secure future financing or partnerships? When is the expected timeline for the lawsuit resolution and any possible settlement? What potential downside could the class action lawsuit have on ALT's share price in the short term?
Lawsuits
about 4 hours ago
Read more prnewswire

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Pemvidutide is the only drug currently granted Fast Track Designation in AUD

How does Pemvidetide's market potential compare to existing treatments and competitors in the alcohol use disorder space? What is the expected timeline for clinical‑trial milestones and potential FDA approval for Pemvidetide in AUD? How will the Fast Track designation for Pemvidetide affect Altimmune's valuation and near‑term stock performance?
Regulatory
1 day ago
Read more globenewswire

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Compan...

Are there any insider trading or insider‑information concerns that could lead to further regulatory scrutiny? What is the market's current perception of the lawsuit, and how might it affect short‑term stock volatility? How does this litigation risk compare to recent legal issues faced by comparable biotech firms?
Lawsuits
5 days ago
Read more prnewswire

Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acq...

What steps, if any, is Altimmune taking to mitigate legal risk and communicate with shareholders about the class action? Are there any potential catalyst events (e.g., upcoming FDA filings, trial dates) that could intersect with the lawsuit timeline and further influence the stock? How might the lawsuit affect analyst coverage, target price revisions, and overall market sentiment toward Altimmune?
Lawsuits
5 days ago
Read more prnewswire

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITI...

How might this lawsuit influence the valuation multiples (P/E, EV/EBITDA) used by analysts for ALT? Is there a risk of additional regulatory or SEC investigations stemming from this lawsuit? How could the class action impact the company's relationships with institutional investors and analysts?
Lawsuits
6 days ago
Read more prnewswire

ALT Stock News: Altimmune, Inc. Stockholder Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Altimmune, Inc.

SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) secu...

How might this litigation affect investor sentiment and the stock’s short‑term volatility? Will the lawsuit trigger any covenant breaches or affect covenants in Altimmune's credit facilities? What are the potential short‑term price impacts versus long‑term valuation implications?
Lawsuits
6 days ago
Read more prnewswire

The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class pe...

What strategies can be employed to hedge exposure to ALT given the heightened legal risk and potential for increased volatility? How might the market's perception of ALT's corporate governance and risk management be affected by this legal development? Is there a possibility that the lawsuit could lead to a material adverse change (MAC) clause being triggered in any of ALT's existing financing agreements?
Lawsuits
7 days ago
Read more prnewswire